CN107923897A - 用于诊断和治疗肾上腺脑白质营养不良的方法和组合物 - Google Patents

用于诊断和治疗肾上腺脑白质营养不良的方法和组合物 Download PDF

Info

Publication number
CN107923897A
CN107923897A CN201680041132.6A CN201680041132A CN107923897A CN 107923897 A CN107923897 A CN 107923897A CN 201680041132 A CN201680041132 A CN 201680041132A CN 107923897 A CN107923897 A CN 107923897A
Authority
CN
China
Prior art keywords
marker
expression
level
sphingosine
horizontal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680041132.6A
Other languages
English (en)
Chinese (zh)
Inventor
A·普约尔奥诺弗雷
M·帕特若奥拓
R·潘普洛纳盖斯
A·J·罗帕斯德穆纳安阿瑞格
M·宙斯弗特
S·富尔卡德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut De Recerca Biomedica De Lleida Fundacio Dr Pifarre
Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL
Institucio Catalana de Recerca i Estudis Avancats ICREA
Universitat de Lleida
Administracion General de la Comunidad Autonoma de Euskadi
Original Assignee
Institut De Recerca Biomedica De Lleida Fundacio Dr Pifarre
Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL
Institucio Catalana de Recerca i Estudis Avancats ICREA
Universitat de Lleida
Administracion General de la Comunidad Autonoma de Euskadi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut De Recerca Biomedica De Lleida Fundacio Dr Pifarre, Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL, Institucio Catalana de Recerca i Estudis Avancats ICREA, Universitat de Lleida, Administracion General de la Comunidad Autonoma de Euskadi filed Critical Institut De Recerca Biomedica De Lleida Fundacio Dr Pifarre
Publication of CN107923897A publication Critical patent/CN107923897A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
CN201680041132.6A 2015-07-14 2016-07-14 用于诊断和治疗肾上腺脑白质营养不良的方法和组合物 Pending CN107923897A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15382366.1 2015-07-14
EP15382366.1A EP3118621A1 (en) 2015-07-14 2015-07-14 Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy
PCT/EP2016/066825 WO2017009437A1 (en) 2015-07-14 2016-07-14 Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy

Publications (1)

Publication Number Publication Date
CN107923897A true CN107923897A (zh) 2018-04-17

Family

ID=53776537

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680041132.6A Pending CN107923897A (zh) 2015-07-14 2016-07-14 用于诊断和治疗肾上腺脑白质营养不良的方法和组合物

Country Status (12)

Country Link
US (1) US20190010535A1 (enExample)
EP (2) EP3118621A1 (enExample)
JP (1) JP2018529081A (enExample)
KR (1) KR20180030074A (enExample)
CN (1) CN107923897A (enExample)
AU (1) AU2016293068A1 (enExample)
BR (1) BR112018000749A2 (enExample)
CA (1) CA2991586A1 (enExample)
CL (1) CL2018000078A1 (enExample)
HK (1) HK1253769A1 (enExample)
MX (1) MX2018000464A (enExample)
WO (1) WO2017009437A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US12172017B2 (en) * 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
CN114904142A (zh) 2016-01-20 2022-08-16 赛博恩特医疗器械公司 迷走神经刺激的控制
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11958805B2 (en) * 2017-03-09 2024-04-16 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
EP3668402B1 (en) 2017-08-14 2024-07-31 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
CN107362351B (zh) * 2017-09-04 2020-11-10 上海市儿童医院 Il-36r的拮抗剂在制备镇痛药物中的应用
US12276670B2 (en) 2017-09-29 2025-04-15 The General Hospital Corporation Methods for identifying and treating adrenomyeloneuropathy (AMN)
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
KR102252167B1 (ko) * 2018-11-22 2021-05-17 연세대학교 산학협력단 X-연관 부신백질이영양증 진단용 바이오마커 조성물
AU2020272128B9 (en) 2019-04-12 2025-11-20 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
WO2022245878A1 (en) 2021-05-17 2022-11-24 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
FR3132910A1 (fr) * 2022-02-24 2023-08-25 Universite De Bourgogne Methodes pour le pronostic et le suivi des leucodystrophies peroxysomales
EP4431945A1 (en) * 2023-03-16 2024-09-18 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Biomarkers discriminating the discordant phenotypes of x-adrenoleukodystrophy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1355193A (zh) * 2000-12-01 2002-06-26 复旦大学 一种新的多肽——肾上腺脑白质营养不良相关蛋白10.78和编码这种多肽的多核苷酸
US20140038949A1 (en) * 2011-02-18 2014-02-06 Irm Llc Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2400960T3 (pl) 2009-02-24 2013-08-30 Novartis Ag Metabolity będące analogami ceramidowymi
US20100260755A1 (en) * 2009-04-09 2010-10-14 Medicinova, Inc. Ibudilast and immunomodulators combination
ES2377381B1 (es) * 2010-05-17 2013-03-14 Fundació Institut De Investigació Biomèdica De Bellvitge (Idibell) Uso de una combinación de n-acetil-cisteína y ácido lipoico para la preparación de un medicamento útil para el tratamiento de una enfermedad con daño axonal y lesiones oxidativas concomitantes.
US8747844B2 (en) * 2010-07-30 2014-06-10 Saint Louis University Methods of treating pain
EP2527344A1 (en) * 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2943189B1 (en) * 2013-01-08 2021-03-10 Pathologica LLC Mitoguazone for treatment of progressive multiple sclerosis
AU2014251038A1 (en) * 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1355193A (zh) * 2000-12-01 2002-06-26 复旦大学 一种新的多肽——肾上腺脑白质营养不良相关蛋白10.78和编码这种多肽的多核苷酸
US20140038949A1 (en) * 2011-02-18 2014-02-06 Irm Llc Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANTONELLA DI BIASE 等: "Th 1 cytokine production by peripheral blood mononuclear cells in X-linked adrenoleukodystrophy", 《JOURNAL OF THE NEUROLOGICAL SCIENCES》 *
JORGE GALINO 等: "Oxidative Damage Compromises Energy Metabolism in the Axonal Degeneration Mouse Model of X-Adrenoleukodystrophy", 《ANTIOXIDANTS & REDOX SIGNALING》 *

Also Published As

Publication number Publication date
JP2018529081A (ja) 2018-10-04
AU2016293068A1 (en) 2018-02-01
BR112018000749A2 (pt) 2018-09-04
WO2017009437A1 (en) 2017-01-19
KR20180030074A (ko) 2018-03-21
MX2018000464A (es) 2018-09-06
EP3118621A1 (en) 2017-01-18
EP3322980B1 (en) 2020-09-09
CA2991586A1 (en) 2017-01-19
US20190010535A1 (en) 2019-01-10
HK1253769A1 (zh) 2019-07-05
EP3322980A1 (en) 2018-05-23
CL2018000078A1 (es) 2018-07-06

Similar Documents

Publication Publication Date Title
CN107923897A (zh) 用于诊断和治疗肾上腺脑白质营养不良的方法和组合物
Xuan et al. Development of a high coverage pseudotargeted lipidomics method based on ultra-high performance liquid chromatography–mass spectrometry
JP7036805B2 (ja) 肝疾患関連バイオマーカーおよびその使用方法
EP2126589A2 (en) Metabolic markers of diabetic conditions and methods of use thereof
JP2010519543A5 (enExample)
US20120238028A1 (en) Means and Methods for Diagnosing Multiple Sclerosis
US9541565B2 (en) Biomarkers for sensitive detection of statin-induced muscle toxicity
CN103502820A (zh) 用于他汀引发的肌肉毒性的灵敏检测的生物标志物
JP7605502B2 (ja) Ｄｍａｒｄに対する患者の応答を予測する方法
Blackmore et al. Metabolomic profile overlap in prototypical autoimmune humoral disease: a comparison of myasthenia gravis and rheumatoid arthritis
CN114980801A (zh) 阿尔茨海默氏病的评价和治疗方法及其应用
WO2021158720A1 (en) Disease detection and treatment based on phenylacetyl glutamine levels
Zhang et al. DI/LC-MS/MS-based metabolic profiling for identification of early predictive serum biomarkers of metritis in transition dairy cows
CA3127522A1 (en) Detection of risk of pre-eclampsia in obese pregnant women
Moreno et al. Lipidomics as tools for finding biomarkers of intestinal pathology: from irritable bowel syndrome to colorectal cancer
US20150241406A1 (en) Means and Methods for Diagnosing Recurrence of Prostate Cancer After Prostatectomy
US8563318B2 (en) Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
Muta et al. Phosphatidylcholine (18: 0/20: 4), a potential biomarker to predict ethionamide‐induced hepatic steatosis in rats
Xiong et al. Metabolomics Study Revealing Purines as Potential Diagnostic Biomarkers of Acute Respiratory Distress Syndrome in Patients with Community─ Acquired Pneumonia
Diab The Metabolome and Lipidome of Ulcerative Colitis
Jain et al. Identification of novel plasma lipid markers of cardiovascular disease risk in White and Black women
Palese et al. Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of Parkinson’s disease
Wilson Metabolic and Inflammatory Biomarker Profiling in Adolescents with Obesity and Insulin Resistance
EP2508895B1 (en) Biomarkers for sensitive detection of statin-induced muscle toxicity
KR20230054966A (ko) 항-tnf 제제에 대한 반응성 예측용 바이오마커 조성물 및 이를 이용한 항-tnf 제제에 대한 반응성 예측 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180417